123 related articles for article (PubMed ID: 2445821)
1. Immunologic competence of B cells subjected to constitutive c-myc oncogene expression in immunoglobulin heavy chain enhancer myc transgenic mice.
Vaux DL; Adams JM; Alexander WS; Pike BL
J Immunol; 1987 Dec; 139(11):3854-60. PubMed ID: 2445821
[TBL] [Abstract][Full Text] [Related]
2. The transgenic window on lymphoid malignancy.
Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
[TBL] [Abstract][Full Text] [Related]
3. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
4. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1988; 3(3):271-9. PubMed ID: 3144697
[TBL] [Abstract][Full Text] [Related]
5. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice.
Langdon WY; Harris AW; Cory S; Adams JM
Cell; 1986 Oct; 47(1):11-8. PubMed ID: 3093082
[TBL] [Abstract][Full Text] [Related]
6. Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E mu-myc transgenic mice.
Alexander WS; Schrader JW; Adams JM
Mol Cell Biol; 1987 Apr; 7(4):1436-44. PubMed ID: 3037318
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice.
Jacobsen KA; Prasad VS; Sidman CL; Osmond DG
Blood; 1994 Oct; 84(8):2784-94. PubMed ID: 7522642
[TBL] [Abstract][Full Text] [Related]
8. The anti-Dextran response of scid mice transgenic for the heavy chain of a Dextran specific IgM antibody.
Nandy A; Geppert M; Waldschütz R; Lehle G
Cell Immunol; 1996 Jun; 170(2):168-77. PubMed ID: 8660815
[TBL] [Abstract][Full Text] [Related]
9. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
10. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
11. Transformation of bone marrow cells from E mu-myc transgenic mice by Abelson murine leukemia virus and Harvey murine sarcoma virus.
Dyall-Smith D; Cory S
Oncogene Res; 1988 May; 2(4):403-9. PubMed ID: 2840624
[TBL] [Abstract][Full Text] [Related]
12. Role of c-myc and CD45 in spontaneous and anti-receptor-induced apoptosis in adult murine B cells.
Scott DW; Lamers M; Köhler G; Sidman CL; Maddox B; Carsetti R
Int Immunol; 1996 Sep; 8(9):1375-85. PubMed ID: 8921415
[TBL] [Abstract][Full Text] [Related]
13. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
14. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A; Harris AW; Bath ML; Cory S
Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
[TBL] [Abstract][Full Text] [Related]
15. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
16. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
Roland J; Morello D
Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
[TBL] [Abstract][Full Text] [Related]
17. B cells genetically deficient in the c-Rel transactivation domain have selective defects in germline CH transcription and Ig class switching.
Zelazowski P; Carrasco D; Rosas FR; Moorman MA; Bravo R; Snapper CM
J Immunol; 1997 Oct; 159(7):3133-9. PubMed ID: 9317110
[TBL] [Abstract][Full Text] [Related]
18. High frequency of myelomonocytic tumors in aging E mu L-myc transgenic mice.
Möröy T; Fisher PE; Lee G; Achacoso P; Wiener F; Alt FW
J Exp Med; 1992 Feb; 175(2):313-22. PubMed ID: 1310099
[TBL] [Abstract][Full Text] [Related]
19. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
20. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.
Nussenzweig MC; Schmidt EV; Shaw AC; Sinn E; Campos-Torres J; Mathey-Prevot B; Pattengale PK; Leder P
Nature; 1988 Dec; 336(6198):446-50. PubMed ID: 3143076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
